MoonLake Immunotherapeutics (MLTX) Cash from Operations (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Cash from Operations of 66286000.0 for Q1 2026, down 73.8% year-over-year from 252966583.95 in Q1 2025, and down 12.74% quarter-over-quarter from 58794000.0 in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Cash from Operations (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Cash from Operations history runs 6 years deep, the most recent figure standing at 66286000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 73.8% year-over-year to 66286000.0; the TTM figure through Mar 2026 stood at 224153000.0 (down 60.36% YoY), while the FY2025 annual figure was 196007000.0, down 68.12% from the prior year.
- Cash from Operations for Q1 2026 stood at 66286000.0, down from 58794000.0 in the prior quarter.
- The five-year high for Cash from Operations was 9024427.0 in Q1 2023, with the low at 66286000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 20760383.0 (2022), against an average of 28091288.24.
- Peak annual rise in Cash from Operations reached 67.03% in 2022, while the deepest fall reached 13060.13% in 2022.
- MoonLake Immunotherapeutics' Cash from Operations stood at 11595982.0 in 2022, then declined by 6.45% to 12344159.0 in 2023, then slumped by 292.68% to 48473000.0 in 2024, then fell by 21.29% to 58794000.0 in 2025, then dropped by 12.74% to 66286000.0 in 2026.
- Business Quant data shows MLTX's Cash from Operations at 66286000.0 in Q1 2026, 58794000.0 in Q4 2025, and 44543000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | -55.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.56 Mn |
| Jun 30, 2026 | -55.56 Mn |
| Mar 31, 2026 | -66.29 Mn |
| Mar 31, 2026 | -66.29 Mn |
| Dec 31, 2025 | -58.79 Mn |
| Dec 31, 2025 | -58.79 Mn |
| Sep 30, 2025 | -44.54 Mn |
| Sep 30, 2025 | -44.54 Mn |
| Jun 30, 2025 | -54.53 Mn |
| Jun 30, 2025 | -54.53 Mn |
| Mar 31, 2025 | -38.14 Mn |
| Mar 31, 2025 | -38.14 Mn |
| Dec 31, 2024 | -48.47 Mn |
| Dec 31, 2024 | -48.47 Mn |
| Sep 30, 2024 | -25.28 Mn |
| Sep 30, 2024 | -25.28 Mn |
| Jun 30, 2024 | -27.89 Mn |
| Jun 30, 2024 | -27.89 Mn |
| Mar 31, 2024 | -14.95 Mn |
| Mar 31, 2024 | -14.95 Mn |